These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 23617353

  • 1. Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives.
    Lee JA, Bubendorf L, Stahel R, Peters S.
    Expert Rev Anticancer Ther; 2013 May; 13(5):625-36. PubMed ID: 23617353
    [Abstract] [Full Text] [Related]

  • 2. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
    Di Maio M, De Marinis F, Hirsch FR, Gridelli C.
    Int J Oncol; 2014 Aug; 45(2):509-15. PubMed ID: 24859689
    [Abstract] [Full Text] [Related]

  • 3. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.
    Malik SM, Maher VE, Bijwaard KE, Becker RL, Zhang L, Tang SW, Song P, Liu Q, Marathe A, Gehrke B, Helms W, Hanner D, Justice R, Pazdur R.
    Clin Cancer Res; 2014 Apr 15; 20(8):2029-34. PubMed ID: 24573551
    [Abstract] [Full Text] [Related]

  • 4. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL, Wenger SD, Kim M, Thompson LA.
    Ann Pharmacother; 2013 Feb 15; 47(2):189-97. PubMed ID: 23386065
    [Abstract] [Full Text] [Related]

  • 5. Economic analysis of ALK testing and crizotinib therapy for advanced non-small-cell lung cancer.
    Lu S, Zhang J, Ye M, Wang B, Wu B.
    Pharmacogenomics; 2016 Jun 15; 17(9):985-94. PubMed ID: 27266545
    [Abstract] [Full Text] [Related]

  • 6. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ, Shapiro GI.
    Curr Opin Investig Drugs; 2010 Dec 15; 11(12):1477-90. PubMed ID: 21154129
    [Abstract] [Full Text] [Related]

  • 7. Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review.
    Yi ES, Chung JH, Kulig K, Kerr KM.
    Mol Diagn Ther; 2012 Jun 01; 16(3):143-50. PubMed ID: 22506598
    [Abstract] [Full Text] [Related]

  • 8. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.
    Ou SH.
    Drug Des Devel Ther; 2011 Jun 01; 5():471-85. PubMed ID: 22162641
    [Abstract] [Full Text] [Related]

  • 9. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G, Stahel RA, Rosell R, Thatcher N, Soria JC.
    Eur J Cancer; 2012 May 01; 48(7):961-73. PubMed ID: 22397764
    [Abstract] [Full Text] [Related]

  • 10. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
    Toyokawa G, Seto T.
    Clin Lung Cancer; 2014 Sep 01; 15(5):313-9. PubMed ID: 24984564
    [Abstract] [Full Text] [Related]

  • 11. Treatment and detection of ALK-rearranged NSCLC.
    Peters S, Taron M, Bubendorf L, Blackhall F, Stahel R.
    Lung Cancer; 2013 Aug 01; 81(2):145-54. PubMed ID: 23769207
    [Abstract] [Full Text] [Related]

  • 12. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer.
    Li S, Qi X, Huang Y, Liu D, Zhou F, Zhou C.
    Clin Lung Cancer; 2015 Mar 01; 16(2):86-91. PubMed ID: 25458559
    [Abstract] [Full Text] [Related]

  • 13. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
    Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, Klempner SJ, Firozvi K, Frampton GM, Molina JR, Menon S, Brahmer JR, MacMahon H, Nowak J, Ou SH, Zauderer M, Ladanyi M, Zakowski M, Fischbach N, Ross JS, Stephens PJ, Miller VA, Wakelee H, Ganesan S, Salgia R.
    Oncologist; 2016 Jun 01; 21(6):762-70. PubMed ID: 27245569
    [Abstract] [Full Text] [Related]

  • 14. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Morgan P, Woolacott N, Biswas M, Mebrahtu T, Harden M, Hodgson R.
    Pharmacoeconomics; 2017 Sep 01; 35(9):909-919. PubMed ID: 28342113
    [Abstract] [Full Text] [Related]

  • 15. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.
    Pailler E, Adam J, Barthélémy A, Oulhen M, Auger N, Valent A, Borget I, Planchard D, Taylor M, André F, Soria JC, Vielh P, Besse B, Farace F.
    J Clin Oncol; 2013 Jun 20; 31(18):2273-81. PubMed ID: 23669222
    [Abstract] [Full Text] [Related]

  • 16. Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer.
    Ou SH.
    Expert Rev Anticancer Ther; 2012 Feb 20; 12(2):151-62. PubMed ID: 22316363
    [Abstract] [Full Text] [Related]

  • 17. Treatment of ALK-positive non-small cell lung cancer.
    Bang YJ.
    Arch Pathol Lab Med; 2012 Oct 20; 136(10):1201-4. PubMed ID: 23020724
    [Abstract] [Full Text] [Related]

  • 18. Crizotinib in the treatment of non--small-cell lung cancer.
    Rothschild SI, Gautschi O.
    Clin Lung Cancer; 2013 Sep 20; 14(5):473-80. PubMed ID: 23790969
    [Abstract] [Full Text] [Related]

  • 19. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
    Pilotto S, Peretti U, Novello S, Rossi G, Milella M, Giaj Levra M, Ciuffreda L, Massari F, Brunelli M, Tortora G, Bria E.
    Expert Opin Pharmacother; 2013 Apr 20; 14(5):597-608. PubMed ID: 23472711
    [Abstract] [Full Text] [Related]

  • 20. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
    Shi R, Varella-Garcia M, Li M, Ludkovski O, Danesh A, Ng C, Pham NA, Pugh T, Shepherd FA, Tsao MS.
    J Thorac Oncol; 2016 Dec 20; 11(12):2248-2252. PubMed ID: 27613526
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.